Nanobody-Based CTLA4 Inhibitors for Immune Checkpoint Blockade Therapy of Canine Cancer Patients

The authors developed, characterized and assessed whether chimeric heavy chain only antibodies against CTLA4 were viable therapeutic candidates for the treatment of canine cancers.